Profile data is unavailable for this security.
About the company
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
- Revenue in USD (TTM)9.68m
- Net income in USD-222.74m
- Incorporated2015
- Employees118.00
- LocationImmunome Inc18702 N. CREEK PARKWAY, SUITE 100BOTHELL 98011United StatesUSA
- Phone+1 (610) 321-3700
- Fax+1 (302) 655-5049
- Websitehttps://immunome.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | 190.41m | 20.48m | 2.02bn | 182.00 | 252.70 | 4.54 | 88.03 | 10.59 | 0.1546 | 0.1546 | 3.61 | 8.61 | 0.4256 | -- | -- | 1,046,181.00 | 4.67 | -28.03 | 5.13 | -30.82 | 98.58 | -- | 10.97 | -130.73 | 5.55 | -- | 0.0997 | -- | -- | -- | 111.64 | -- | 59.83 | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 2.10bn | 128.00 | 55.59 | 6.56 | 49.36 | 10.19 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Grail Inc | 147.17m | -408.35m | 2.12bn | 1.00k | -- | 0.8234 | -- | 14.42 | -11.18 | -11.18 | 4.01 | 63.92 | 0.0498 | -- | 7.62 | -- | -13.83 | -- | -14.21 | -- | 48.46 | -- | -277.47 | -- | -- | -- | -- | -- | 17.18 | -- | 79.85 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 874.84m | 263.86m | 2.16bn | 435.00 | 7.17 | -- | 8.11 | 2.47 | 1.20 | 1.20 | 4.00 | -0.5593 | 1.74 | 2.83 | 9.41 | 2,011,120.00 | 52.53 | -18.78 | 81.42 | -25.41 | 97.82 | 97.60 | 30.16 | -23.15 | 2.03 | 4.99 | 1.34 | -- | 94.10 | 117.89 | 396.87 | -- | 36.86 | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.19bn | 125.00 | -- | 5.78 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.32bn | 51.00 | -- | 4.02 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.37bn | 78.00 | -- | 4.33 | -- | 769.76 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.45bn | 118.00 | -- | 7.72 | -- | 253.17 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.48bn | 624.00 | -- | 11.33 | -- | 8.96 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | 443,871.80 | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -30.92 | -- |
| Disc Medicine Inc | 0.00 | -212.18m | 2.54bn | 155.00 | -- | 3.41 | -- | -- | -5.98 | -5.98 | 0.00 | 19.53 | 0.00 | -- | -- | 0.00 | -32.55 | -30.94 | -34.12 | -32.93 | -- | -- | -- | -- | -- | -- | 0.0379 | -- | -- | -- | -94.03 | -- | -- | -- |
| Wave Life Sciences Ltd | 42.73m | -204.38m | 2.61bn | 317.00 | -- | 5.01 | -- | 61.02 | -1.21 | -1.21 | 0.2534 | 2.80 | 0.0863 | -- | 31.67 | 134,785.50 | -41.26 | -44.67 | -52.09 | -71.58 | -- | -- | -478.33 | -208.12 | -- | -- | 0.00 | -- | -60.55 | 16.31 | -110.68 | -- | -11.71 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.61bn | 240.00 | -- | 3.33 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Travere Therapeutics Inc | 490.73m | -50.26m | 2.72bn | 497.00 | -- | 23.38 | 259.86 | 5.55 | -0.603 | -0.3293 | 5.30 | 1.26 | 0.8184 | 1.71 | 9.15 | 987,382.30 | -8.38 | -37.69 | -11.99 | -48.59 | 97.89 | 96.60 | -10.24 | -116.71 | 2.70 | -- | 0.7308 | -- | 110.45 | 19.87 | 84.32 | -- | 18.81 | -- |
| Veracyte Inc | 517.15m | 66.35m | 2.86bn | 755.00 | 44.20 | 2.18 | 32.60 | 5.53 | 0.8147 | 0.8147 | 6.45 | 16.50 | 0.3822 | 7.31 | 11.34 | 684,960.30 | 4.90 | -1.69 | 5.17 | -1.78 | 70.10 | 67.87 | 12.83 | -5.22 | 7.81 | -- | 0.00 | -- | 16.01 | 34.50 | 174.89 | -- | 27.81 | -- |
| Vera Therapeutics Inc | 0.00 | -299.62m | 2.88bn | 249.00 | -- | 4.77 | -- | -- | -4.66 | -4.66 | 0.00 | 8.48 | 0.00 | -- | -- | 0.00 | -43.10 | -46.45 | -45.69 | -50.25 | -- | -- | -- | -- | -- | -- | 0.1102 | -- | -- | -- | -96.92 | -- | 44.79 | -- |
Data as of Mar 03 2026. Currency figures normalised to Immunome Inc's reporting currency: US Dollar USD
63.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 16.54m | 14.99% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 13.42m | 12.17% |
| Point72 Asset Management LPas of 31 Dec 2025 | 7.03m | 6.38% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.35m | 5.76% |
| Redmile Group LLCas of 31 Dec 2025 | 5.72m | 5.18% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.21m | 4.73% |
| PRIMECAP Management Co.as of 31 Dec 2025 | 4.69m | 4.25% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.87m | 3.51% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 3.71m | 3.36% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 3.28m | 2.97% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
